Patient and GVHD characteristics, prognosis cohort
| . | cGVHD (n = 114) . | No cGVHD (n = 678) . | P . |
|---|---|---|---|
| Sample draw day, median (range) | 96 (82-122) | 96 (58-133) | .25 |
| Prior acute GVHD, n (%)* | |||
| Grade 0-1 | 66 (62) | 384 (62) | |
| Grade 2-4 | 41 (38) | 232 (38) | .90 |
| On steroids at sample draw, n (%) | |||
| No | 44 (39) | 346 (51) | |
| Yes | 70 (61) | 332 (49) | .02 |
| Donor/recipient sex, n (%)† | |||
| Female/male | 34 (30) | 136 (20) | |
| Other | 80 (70) | 539 (80) | .02 |
| Donor, n (%)† | |||
| Matched related | 46 (40) | 231 (34) | |
| Matched unrelated | 45 (39) | 279 (41) | |
| Mismatched | 23 (20) | 165 (24) | .39 |
| Stem cell source, n (%) | |||
| PBSC | 96 (84) | 545 (80) | |
| Bone marrow | 9 (8) | 54 (8) | |
| Cord blood | 9 (8) | 79 (12) | .49 |
| Age at enrollment, n (%) | |||
| 0-49 | 45 (39) | 266 (39) | |
| 50+ | 69 (61) | 412 (61) | .96 |
| Conditioning, n (%) | |||
| Myeloablative | 48 (42) | 303 (45) | |
| Nonmyeloablative | 66 (58) | 375 (55) | .61 |
| . | cGVHD (n = 114) . | No cGVHD (n = 678) . | P . |
|---|---|---|---|
| Sample draw day, median (range) | 96 (82-122) | 96 (58-133) | .25 |
| Prior acute GVHD, n (%)* | |||
| Grade 0-1 | 66 (62) | 384 (62) | |
| Grade 2-4 | 41 (38) | 232 (38) | .90 |
| On steroids at sample draw, n (%) | |||
| No | 44 (39) | 346 (51) | |
| Yes | 70 (61) | 332 (49) | .02 |
| Donor/recipient sex, n (%)† | |||
| Female/male | 34 (30) | 136 (20) | |
| Other | 80 (70) | 539 (80) | .02 |
| Donor, n (%)† | |||
| Matched related | 46 (40) | 231 (34) | |
| Matched unrelated | 45 (39) | 279 (41) | |
| Mismatched | 23 (20) | 165 (24) | .39 |
| Stem cell source, n (%) | |||
| PBSC | 96 (84) | 545 (80) | |
| Bone marrow | 9 (8) | 54 (8) | |
| Cord blood | 9 (8) | 79 (12) | .49 |
| Age at enrollment, n (%) | |||
| 0-49 | 45 (39) | 266 (39) | |
| 50+ | 69 (61) | 412 (61) | .96 |
| Conditioning, n (%) | |||
| Myeloablative | 48 (42) | 303 (45) | |
| Nonmyeloablative | 66 (58) | 375 (55) | .61 |